A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University Cancer Hospital & Institute
About this trial
This is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.
Eligibility criteria
Qualifiers
Subjects voluntarily participate in clinical research;
Age ≥18 years old;
Eastern Cooperative Oncology Group (ECOG) score 0-1;
Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, histologically indolent lymphoma to diffuse large B-cell lymphoma; CD20 positive;
Disqualifiers
Prior antitumor therapy with insufficient washout period.
Previous treatment with allogeneic cell and gene therapy (such as CAR-T); Except subjects with evidence that previous allogeneic cell and gene therapy products (such as CAR-positive T cells and CAR transgenes) in the subject have been below the lower limit of detection;
Previously received allogeneic hematopoietic stem cell transplantation;
Previously received gene therapy;
Trial design
Treatments tested in this trial
- LUCAR-20SP cells
Treatment groups
42 Participants
are divided into 1 treatment groupSponsors and collaborators
Peking University Cancer Hospital & Institute
Lead sponsor
Nanjing Legend Biotech Co.
Collaborator
Beijing Boren Hospital
Collaborator
Henan Cancer Hospital
Collaborator
Source ClinicalTrials.gov